CClinicalTrials.gg
CompletedNCT06613022(IASTM)Updated Sep 25, 2024

Effects of Instrument Assisted Soft Tissue Mobilization on Healthy Tissue Regarding Range of Motion and Grip Strength

An interventional study of Instrument Assisted Soft Tissue Mobilization first Control second and Control first Instrument Assisted Soft Tissue Mobilization second in Healthy, sponsored by Beth Marschner. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Beth Marschner · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2024, registered Sep 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to study the effects of instrument assisted soft tissue mobilization (IASTM) in healthy adult volunteers. The main questions it aims to answer are:

  • Does IASTM treatment have an effect on range of motion (ROM) as measured in the elbow, wrist and thumb?
  • Does IASTM treatment have an effect on grip strength? Researchers will compare pre-test and post-test IASTM treatment intervention data to the pre-test and post-test data of the no treatment control intervention to see if IASTM works to change ROM and/or grip strength.

Participants will:

  • Complete a questionnaire on medical history and injury background
  • Have elbow, wrist, and thumb range of motion (ROM) measurements taken on both upper extremities using a goniometer
  • Undergo grip strength testing using a JAMAR hand dynamometer in three positions on both upper extremities
  • Be randomly assigned to either IASTM first treatment group or the wait/control first group
  • Receive IASTM treatment techniques including application of emollient to the skin to reduce friction on the surface followed by scanning the forearm wrist flexors and wrist extensors and the biceps and triceps using the HG8-Scanner tool and then the concave tool corresponding to the size of the structure being treated will be used (HG6-Large Multi-Curve, HG5-Medium Multi-Curve, HG4-Small Multi-Curve) in each direction for a total treatment time of 20 minutes for both upper extremities in all listed areas.
  • Simply wait for 20 minutes (the duration of time treatment with IASTM would require) when assigned to the control group.
  • Complete elbow, wrist and thumb range of motion and grip strength measurement testing at the end of the first session.
  • Return within fourteen days after the first session in order to undergo the opposite experience (IASTM first means wait/control second and vice versa).
  • Undergo the same baseline pre-test measurements for range of motion and grip strength as the first session.
  • Experience the opposite treatment group for the same time period as the first session.
  • Undergo the post-test range of motion and grip strength testing at the end of the second session for data comparison.
Read the detailed description

No further information to note than what is described in the summary or elsewhere

02

Conditions studied

  • Healthy

Keywords

  • Instrument Assisted Soft Tissue Mobilization
  • Range of Motion
  • Grip Strength
03

In context

Lead sponsor

Beth Marschner is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • A volunteer from a small regional university student body, faculty or staff may participate.

Exclusion criteria

Exclusion Criteria:

  • Acute spinal cord injury with neurological deficits
  • Neurological disorders
  • Acute upper extremity injury such as sprain or strain
  • Any type of upper extremity fracture within the past 12 months
  • Cervical disc pathology with radicular symptoms
  • Use of blood thinning or clotting medications
  • Known connective tissue disorder
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    IASTM First

    This arm of the study received IASTM treatment on the first day and the wait/control on the second day of the study.

    Other: Instrument Assisted Soft Tissue Mobilization first Control second

  • Experimental
    Wait/control First

    This arm of the study waited (was the control) on the first day and received IASTM treatment on the second day of the study.

    Other: Control first Instrument Assisted Soft Tissue Mobilization second

Interventions

  • OtherInstrument Assisted Soft Tissue Mobilization first Control second

    Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.

  • OtherControl first Instrument Assisted Soft Tissue Mobilization second

    This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.

06

What researchers measure

Primary outcomes

  1. Range of Motion

    Bilateral elbow flexion and extension, wrist flexion, extension, ulnar deviation and radial deviation as well as thumb flexion, abduction and extension range of motion measurements were taken in sitting using a goniometer.

    Time frame: From baseline to end of session at one hour

  2. Grip Strength

    Grip strength was assessed bilaterally using a JAMAR hand dynamometer. Three positions were tested. First the participant flexed their shoulder to 90 degrees with the elbow kept straight. Then the participant kept their arm down and their side with the elbow bent to 90 degrees. Finally the participant kept their arm down and straightened the elbow. Three trials were used for each position.

    Time frame: From baseline to end of session at one hour

07

Study locations

1 site
  • Minot State University
    Minot, North Dakota 58707, United States
08

References and documents

Individual participant data

Plan to share: No — The individual participant data is not the main focus of this study. The overall findings of the study with the larger number of participants to look at the trend is what will be shared (presented or published). The IRB proposal for this study included confidentiality of each individual participant as that will be maintained, but the global findings are what will be shared after data analysis for comparison.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06613022
Lead sponsor
Beth Marschner
Collaborators
Minot State University
Responsible party
Beth Marschner (Assistant Professor, Minot State University) — Sponsor-investigator
First posted
Sep 25, 2024
Start date
Jan 8, 2024
Primary completion
Feb 29, 2024
Completion
Feb 29, 2024
Last update
Sep 25, 2024

Study contacts

Beth Marschner, DPT
principal investigator · Minot State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion